Compare RLMD & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | QTRX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.3M | 352.7M |
| IPO Year | N/A | 2017 |
| Metric | RLMD | QTRX |
|---|---|---|
| Price | $4.34 | $7.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $10.33 |
| AVG Volume (30 Days) | ★ 1.1M | 867.6K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $130,203,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $28.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $4.05 |
| 52 Week High | $5.12 | $12.41 |
| Indicator | RLMD | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 65.13 |
| Support Level | $3.95 | $7.44 |
| Resistance Level | $4.72 | $7.81 |
| Average True Range (ATR) | 0.46 | 0.40 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 62.79 | 64.98 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.